In the latest market close, Adaptimmune Therapeutics PLC (ADAP) reached $0.55, with a -1.79% movement compared to the previous day. This change lagged the S&P 500’s 0.48% loss on the day. At the same time, the Dow lost 1.12%, and the tech-heavy Nasdaq gained 0.38%.
Prior to today’s trading, shares of the company had lost 28.72% over the past month. This has lagged the Medical sector’s loss of 5.4% and the S&P 500’s loss of 2.65% in that time.
Analysts and investors alike will be keeping a close eye on the performance of Adaptimmune Therapeutics PLC in its upcoming earnings disclosure. The company’s upcoming EPS is projected at -$0.20, signifying a 16.67% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $5 million, indicating a 28.67% decline compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.52 per share and a revenue of $62.7 million, signifying shifts of +49.02% and +130.96%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Adaptimmune Therapeutics PLC. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we’ve crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Adaptimmune Therapeutics PLC is carrying a Zacks Rank of #3 (Hold).
The Medical – Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 69, positioning it in the top 28% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof… and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with “black gold.”
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you’ll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don’t want to miss these recommendations.
Download your free report now to see them.
Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.